Fax: (011) +49-6221-421302
Beta blocker use and colorectal cancer risk†
Population-based case-control study
Version of Record online: 14 MAY 2012
Copyright © 2012 American Cancer Society
Volume 118, Issue 16, pages 3911–3919, 15 August 2012
How to Cite
Jansen, L., Below, J., Chang-Claude, J., Brenner, H. and Hoffmeister, M. (2012), Beta blocker use and colorectal cancer risk. Cancer, 118: 3911–3919. doi: 10.1002/cncr.26727
We thank Ute Handte-Daub for her excellent technical assistance; the study participants; the interviewers who collected the baseline data; the Cancer Registry of Rhineland-Palatinate; and the following hospitals that recruited patients for this study: Chirurgische Universitätsklinik Heidelberg, Klinik am Gesundbrunnen Heilbronn, St. Vincentiuskrankenhaus Speyer, St Josefskrankenhaus Heidelberg, Chirurgische Universitätsklinik Mannheim, Diakonissenkrankenhaus Speyer, Krankenhaus Salem Heidelberg, Kreiskrankenhaus Schwetzingen, St Marien- und St. Annastiftkrankenhaus Ludwigshafen, Klinikum Ludwigshafen, Stadtklinik Frankenthal, Diakoniekrankenhaus Mannheim, Kreiskrankenhaus Sinsheim, Klinikum am Plattenwald Bad Friedrichshall, Kreiskrankenhaus Weinheim, Kreiskrankenhaus Eberbach, Kreiskrankenhaus Buchen, Kreiskrankenhaus Mosbach, Enddarmzentrum Mannheim, Kreiskrankenhaus Brackenheim.
- Issue online: 3 AUG 2012
- Version of Record online: 14 MAY 2012
- Manuscript Accepted: 7 NOV 2011
- Manuscript Revised: 11 OCT 2011
- Manuscript Received: 26 AUG 2011
- colorectal cancer;
- antihypertensive agents;
- beta blocker;
- case-control studies
Recently, it has been postulated that long-term use of beta blockers might decrease the risk of certain types of cancer because of weakening of norepinephrine signaling. Previous studies on colorectal cancer (CRC) yielded inconsistent results, but lacked information on covariates. Thus, the authors investigated the association of beta blocker use and CRC risk in a large population-based case-control study (DACHS study).
Between 2003 and 2007, information on beta blocker use and potential confounders was collected by personal interviews for 1762 CRC cases and 1708 control individuals from Germany. The association of CRC risk and beta blocker use and subclasses of beta blockers was estimated by multiple logistic regression. In addition, site- and stage-specific analyses were performed.
After adjustment for covariates, no association was observed with beta blocker use (odds ratio [OR], 1.05; 95% confidence interval [CI], 0.86-1.29) or with duration of beta blocker use. Also, the analysis by subclasses of beta blockers (cardioselectivity) and active ingredients (metoprolol, bisoprolol, carvedilol, and atenolol) or by CRC subsite showed no associations. In stage-specific analyses, long-term beta blocker use (6+ years) was associated with a significantly higher risk of stage IV CRC (OR, 2.02; 95% CI, 1.25-3.27).
Our adjusted results do not support the hypothesis that beta blocker use is associated with decreased risk of CRC. In contrast, we found a positive association of long-term beta blocker use and risk of stage IV CRC. The latter result should be further evaluated in future studies. Cancer 2012.© 2012 American Cancer Society.